More News of Interest

Swift Biosciences and BillionToOne Partner Together for Commercialization and Manufacturing of EUA Approved COVID-19 Test

September 29, 2020

Swift Biosciences, a leader in Next-Generation Sequencing Manufacturing & Technology and BillionToOne, a precision diagnostics company today announced that Swift Bioscience will be the exclusive distributor of BillionToOne’s RNA extraction-free, Emergency Use Authorization (EUA) COVID-19 Test Kit for high capacity testing of up to a million tests per day. The test is designed to detect the virus that causes COVID-19 in respiratory specimens obtained from nasal swabs, nasopharyngeal swabs, or oropharyngeal swabs.

Swift Biosciences notes: The BillionToOne COVID-19 test uses different sets of instruments and chemicals from existing COVID-19 tests, enabling labs to unlock a new set of unused capacity. The BillionToOne test sequences the virus’ genome – making the test sensitive, specific, and accurate compared to other COVID-19 tests on the market.  Most notable, this test does not require RNA extraction which is costly, time-consuming, and critical supply chain demands due to flu season will not negatively affect this workflow.  Additionally, the test is easily adaptable for any clinical labs with Sanger Sequencers and requires minimal training.

BillionToOne approached Swift Biosciences in April of 2020 and asked for their assistance to manufacture and provide quality assurance shipping and logistics.  Swift has provided BillionToOne with 60,000 RUO reactions that have been adopted by DASA, the biggest medical diagnostics laboratory in Brazil.  With the EUA approval from the U.S. Food and Drug Administration (FDA), Swift will be leading all worldwide commercial efforts, except for Brazil.

“Early in the pandemic, Swift was quick to pivot and offer products for sequencing the SARS-CoV-2 genome and associated receptors like ACE2.  By including the BillionToOne’s COVID Diagnostic Test Kit into Swift’s product portfolio, it allows us the opportunity to provide the full complement of tools to assist in the fight against COVID-19 in ways that were not possible before.  Clinical laboratories can use their excess Sanger instruments to full capacity to do over 3,000 test per day per instrument,” said Nathan Wood, CEO of Swift Biosciences.

The BilliontoOne qSanger-COVID-19 Assay is available for immediate purchase, and shipment through SwiftBioSci.com for North America and Swift’s global distribution network.

Latest Posts

spot_img

Don't Miss

Stay on top - Get Medical Device News Magazine daily news in your inbox

Enter your email address:

Delivered by FeedBurner